Navigation Links
Mylan Reports Adjusted Diluted EPS of $0.45 for the Quarter, a 36% Increase over Prior Year Quarter; and $1.61 for the Year, a 24% Increase over Prior Year
Date:2/24/2011

60;During 2009, within Generics, Mylan recognized $28.5 million of incremental other revenue resulting from the cancellation of product development agreements for which the revenue had been previously deferred.  There was no such revenue recognized during the current year.  

A tabular summary of the Company's revenues for the years ended December 31, 2010, and 2009, is included at the end of this release.

Generics third party net sales were $4.98 billion in 2010, compared to $4.61 billion in prior year.

Third party net sales from North America were $2.36 billion in 2010, compared to $2.09 billion for the prior year, representing an increase of $265.0 million, or 12.6%. The increase was driven by increased volume, new product launches and incremental revenue from the Bioniche Pharma acquisition, partially offset by unfavorable pricing on certain existing products, including divalproex sodium extended-release (divalproex ER) tablets, the generic version of Abbott Laboratories' Depakote® ER, for which Mylan had exclusivity for a portion of 2009.

New products launched in the US and Canada contributed sales of $158.6 million, over half of which consisted of valacyclovir hydrochloride tablets, the generic version of GlaxoSmithKline's Valtrex®, and minocycline hydrochloride extended release tablets, the generic version of Medicis Pharmaceutical Corporation's Solodyn® ER.  The Company's ability to continue to be a stable and reliable source of supply to the market resulted in the favorable volume on its existing product base.

Third party net sales from EMEA were $1.55 billion for 2010, compared to $1.64 billion for the prior year, a decrease of $90.8 million, or 5.5%. However, translating current year third party net revenues from EMEA at prior year exchange rates would result in a decrease excluding the effect of foreign currency translations of approximately $24 million, or 1%.  This decrease was m
'/>"/>

SOURCE Mylan Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18

Related biology technology :

1. Mylan Confirms First-to-File Patent Challenge Relating to Lescol(R)
2. Mylan Reports Adjusted Diluted EPS of $0.23 for the Quarter Ended Sept. 30, 2008
3. Cephalon and Eurand File Patent Infringement Lawsuit Against Mylan Pharmaceuticals and Barr Pharmaceuticals
4. Shire Receives FOSRENOL Paragraph IV Notice Letters from Barr Laboratories and Mylan
5. Mylan Reports Adjusted Diluted EPS of $0.26 for the Quarter Ended Dec. 31, 2008, and Adjusted Diluted EPS of $0.80 for the Year Ended Dec. 31, 2008
6. Shire Files Lawsuit Against Mylan for Infringement of FOSRENOL(R) (Lanthanum Carbonate) Patent
7. Mylan Confirms Four First-to-File Challenges
8. Mylans Matrix Receives First Tentative FDA Approval Under PEPFAR for Generic Truvada(R)
9. Mylans Matrix Selected by the Clinton HIV/AIDS Initiative and UNITAID as the Primary Supplier of Five Second-Line and Seven Pediatric HIV/AIDS Treatments
10. Mylan Receives Tentative FDA Approval for Generic Version of Singulair(R)
11. Mylan Again Calls for an End to Authorized Generics During 180-Day Exclusivity Period
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 2014 BioTech News Coverage: Progress ... results of studies and trials.  Companies in focus are: ... LLY ), Gilead Sciences Inc. (NASDAQ: ... ) and Arena Pharmaceuticals Inc. (NASDAQ: ARNA) ... therapeutics for the treatment of cancer, announced that the ...
(Date:9/19/2014)... , The first grants awarded ... Endocrinology (ESPE) Meeting  Investment supports innovative projects ... the field of growth  , EMD Serono, ... , today announced the first recipients of the ... were announced during a Satellite Symposium organized by EMD ...
(Date:9/18/2014)... LONDON , Sept. 18, 2014 ... near-patient testing, is performed outside a clinical laboratory. ... hence in administrating appropriate treatments and medication. POCT ... and prevalence of lifestyle diseases such as diabetes, ... and user-friendly. POCT devices are standardized to minimize ...
(Date:9/18/2014)... , September 18, 2014 /PRNewswire/ ... Markets ( http://www.researchandmarkets.com/research/czvg3s/biocompatible ) has announced ... Materials - Global Strategic Business Report" ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769) ,This report analyzes the ... US$ Million by the following Product ...
Breaking Biology Technology:Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 2Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 3Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 4Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 5Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 6Biotech Companies Pushing Sector Higher With Recent Therapeutic Advancements & Patent Approvals - Company Wins Summary Judgment For Prodrug Patent 7EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 2EMD Serono Awards Grant for Growth Innovation (GGI) for the First Time 3POCT Market in China 2014-2018 2Biocompatible Materials - Global Strategic Business Report 2014 2Biocompatible Materials - Global Strategic Business Report 2014 3
... begun using a network infrastructure developed by Citrix ... over the Internet from a central office, the company ... able to provide 1,600 government employees across 45 departments ... from remote locations, including their homes, according to a ...
... - Working to help cell-phone users take advantage of ... University of Wisconsin-Madison engineers have developed a device that ... on even less battery power. , ,"When you've been ... you can feel how hot it gets," notes Zhenqiang ...
... an Internet search page: top, middle and down. A search ... times its 100 feet long. Today, e-commerce is like a ... then will it will float on the surface and be ... submarine, it will stay caught in some mysterious undercurrents or ...
Cached Biology Technology:Dane County improves law enforcement and community services 2UW-Madison technology to advance cell phones 2UW-Madison technology to advance cell phones 3Does your web site have visibility? 2Does your web site have visibility? 3
(Date:9/18/2014)... algal forests in the eastern Mediterranean Sea pose a ... distribution continues to expand as the climate warms, a ... of researchers led by Dr Adriana Vergs of UNSW ... for Advanced Studies in Spain, is published in the ... surveyed more than 1000 kilometres of coastline in Turkey ...
(Date:9/18/2014)... 2014 Elsevier, a world-leading provider of scientific, ... the Australasian Research Management Society (ARMS), recognized the ... the 5th Scopus Young Researcher of the Year ... at the National Convention Centre and in conjunction ... by guests representing Australia,s and New Zealand,s scientific ...
(Date:9/18/2014)... of the fish world, are the ideal animal in ... They,ve moved from the ocean into tens of thousands ... time changing their skeleton to adapt to the new ... of sticklebacks now have turned up one of the ... simple change in that gene,s regulation in a freshwater ...
Breaking Biology News(10 mins):Tropical fish a threat to Mediterranean Sea ecosystems 2Elsevier and Australasian Research Management Society award scientists at Scopus ceremony 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 2Counting fish teeth reveals regulatory DNA changes behind rapid evolution, adaptation 3
... research group of Dr. Frdric Charron, a researcher at the ... discovery which could help treat spinal cord injuries and neurodegenerative ... issue of the prestigious scientific journal Neuron . Patricia ... the IRCM, are listed as co-authors. The brain is ...
... of the most successful scientists within stem cell research, ... for biotech and pharmaceuticals, BIO 2009 in Atlanta, USA. ... Karolinska Institutet, SwedenBIO and Invest in Sweden Agency. ... one of the most exciting areas in science, and ...
... years ago, it was discovered that bacteria known as ... antibiotics have become the primary therapy used to combat the ... of the world population and is also a primary cause ... resistant to antibiotics. Now a study led by ...
Cached Biology News:Identification of a key molecular pathway required for brain neural circuit formation 2Glutamine supplements show promise in treating stomach ulcers 2Glutamine supplements show promise in treating stomach ulcers 3
Antibodies were affinity purified using epitopes specific to JLP immobilized on solid support....
This issue concentrated on the purification of proteins for specific purposes (i.e. large-scale purification, purification for therapeutic use, etc.)...
Edited by D. Patel (1994) Comprehensive data on gel electrophoresis of proteins, nucleic acids, nucleoproteins and carbohydrates....
The Protein Kinase Factsbooks (2 Volume Set)...
Biology Products: